RIFAPENTINE IS AN INDUCER OF CYTOCHROMES P4503A4 AND P4502C8/9. THEREFORE, RIFAPENTINE MAY INCREASE THE METABOLISM OF OTHER COADMINISTERED DRUGS THAT ARE METABOLIZED BY THESE ENZYMES. ANTICONVULSANTS: EG, PHENYTOIN;
ANTIARRHYTHMICS: EG, DISOPYRAMIDE, MEXILETINE, QUINIDINE, TOCAINIDE;
ANTIBIOTICS: EG, CHLORAMPHENICOL, CLARITHROMYCIN, DAPSONE, DOXYCYCLINE; FLUOROQUINOLONES (SUCH AS CIPROFLOXACIN); ORAL ANTICOAGULANTS: EG, WARFARIN; ANTIFUNGALS: EG, FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE;
BARBITURATES; BENZODIAZEPINES: EG, DIAZEPAM; BETA-BLOCKERS, CALCIUM CHANNEL BLOCKERS: EG, DILTIAZEM, NIFEDIPINE, VERAPAMIL; CORTICOSTEROIDS
CARDIAC GLYCOSIDE PREPARATIONS; CLOFIBRATE; ORAL OR OTHER SYSTEMIC HORMONAL CONTRACEPTIVES; HALOPERIDOL; HIV PROTEASE INHIBITORS: EG, INDINAVIR, RITONAVIR, NELFINAVIR, SAQUINAVIR ; ORAL HYPOGLYCEMIC AGENTS: EG, SULFONYLUREAS; IMMUNOSUPPRESSANTS: EG, CYCLOSPORINE, TACROLIMUS;
LEVOTHYROXINE; NARCOTIC ANALGESICS: EG, METHADONE; PROGESTINS; QUININE;
REVERSE TRANSCRIPTASE INHIBITORS: EG, DELAVIRDINE, ZIDOVUDINE; SILDENAFIL;
THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANTS: EG, AMITRIPTYLINE, NORTRIPTYLINE
PATIENTS USING ORAL OR OTHER SYSTEMIC HORMONAL CONTRACEPTIVES SHOULD BE ADVISED TO CHANGE TO NONHORMONAL METHODS OF BIRTH CONTROL.